News Headlines

  1. Rockwell Automation And Cytiva Launch Platform To Accelerate Digital Transformation For Biopharma Companies 4/29/2026

    Rockwell Automation, Inc., the world’s largest company dedicated to industrial automation and digital transformation, and Cytiva, a Danaher company and a leader in the life sciences industry, are jointly launching the Figurate Supervisory Control and Data Acquisition (SCADA) system designed to remove digital bottlenecks during biopharmaceutical manufacturing.

  2. Thermo Fisher Scientific Expands Plainville Facility With Flagship Bioprocess Design Center To Advance Biologics Development 4/29/2026

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics.

  3. Candel Therapeutics Announces Commercialization Agreement With EVERSANA To Support Potential U.S. Launch Of Aglatimagene Besadenovec In Localized Prostate Cancer 4/29/2026

    Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the “Agreement”) with EVERSANA®, a leading provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer.

  4. Kytopen, T-CURX, And The Fraunhofer IZI Establish Center Of Excellence To Develop Advanced, Non-Viral Cell Therapies 4/29/2026

    Kytopen Corp., a leader in non-viral, continuous flow cellular engineering technologies, T-CURX GmbH ("T-CURX"), a leader in transposon-based CAR-T manufacturing, and Fraunhofer IZI, a developer of novel, clinically-relevant cellular therapies, today announced the establishment of a center of excellence (CoE).

  5. OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval For Generic Semaglutide Injection 4/29/2026

    OneSource Specialty Pharma Limited today announced that its partner Dr. Reddy’s Laboratories Ltd., has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.

  6. Porton Advanced And Dark Horse Consulting Group Announce Memorandum Of Understanding Providing A Streamlined Path To Conducting IITs In China 4/29/2026

    Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally.

  7. Genezen And The Charlotte & Gwenyth Gray Foundation To Cure Batten Disease Announce Manufacturing Partnership For CLN6 Gene Therapy Clinical Trial 4/28/2026

    Genezen, a gene therapy contract development and manufacturing organization (CDMO), and The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease today announced a manufacturing partnership to advance a CLN6 gene therapy into a Phase 1/2 clinical trial.

  8. Emergent BioSolutions And Substipharm Biologics Announce Strategic Manufacturing Partnership To Support Japanese Encephalitis Vaccine In The United States 4/28/2026

    Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese Encephalitis (JE) vaccine, licensed internationally under the brand name IMOJEV® at Emergent’s Canton, Massachusetts facility, and for Emergent to serve as the exclusive distributor of the vaccine to the U.S. government, following potential U.S. Food & Drug Administration (FDA) regulatory endeavors.

  9. Cellares And Cabaletta Bio Sign 10-Year Commercial Supply Agreement To Scale Rese-Cel 4/28/2026

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. for the automated manufacture of rese-cel (resecabtagene autoleucel), Cabaletta’s investigational CAR T cell therapy for autoimmune diseases.

  10. CellProthera Collaborates With Quintessence Biotech To Industrialize Cell Manufacturing Processes Ahead Of Stroke Clinical Trials 4/28/2026

    CellProthera announces a new collaboration to optimize manufacturing processes using Quintessence’s technology, preparing its cell therapy to advance into clinical trials for the treatment of ischemic stroke.